[{"to": "274", "prefix": "sm of Action\n                     \n                        ", "from": "263", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "Bicalutamide", "suffix": " is a non-steroidal androgen receptor inhibitor. It competit"}, {"to": "636", "prefix": "moves the source of androgen.\n                        When ", "from": "625", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " is combined with luteinizing hormone releasing hormone "}, {"to": "842", "prefix": "H analog is not affected. However, in clinical trials with ", "from": "831", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " as a single agent for prostate cancer, rises in serum testo"}, {"to": "1028", "prefix": "        In a subset of patients who have been treated with ", "from": "1017", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " and an LHRH agonist, and who discontinue bicalutamide thera"}, {"to": "1082", "prefix": "with bicalutamide and an LHRH agonist, and who discontinue ", "from": "1071", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " therapy due to progressive advanced prostate cancer, a redu"}, {"to": "1700", "prefix": "\n                           \n                              ", "from": "1689", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "Bicalutamide", "suffix": " is well-absorbed following oral administration, although th"}, {"to": "1832", "prefix": " absolute bioavailability is unknown. Co-administration of ", "from": "1821", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " with food has no clinically significant effect on rate or e"}, {"to": "2229", "prefix": "\n                           \n                              ", "from": "2218", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "Bicalutamide", "suffix": " is highly protein-bound "}, {"to": "2615", "prefix": "\n                           \n                              ", "from": "2604", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "Bicalutamide", "suffix": " undergoes stereospecific metabolism. The S "}, {"to": "3180", "prefix": "              Pharmacokinetics of the active enantiomer of ", "from": "3169", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " in normal males and patients with prostate cancer are prese"}, {"to": "691", "prefix": "                        When bicalutamide is combined with ", "from": "655", "name": "Gonadotropin-Releasing Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D007987", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "luteinizing hormone releasing hormone", "suffix": " "}, {"to": "697", "prefix": "", "from": "694", "name": "Gonadotropin-Releasing Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D007987", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "LHRH", "suffix": ""}, {"to": "772", "prefix": "rapy, the suppression of serum testosterone induced by the ", "from": "769", "name": "Gonadotropin-Releasing Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D007987", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "LHRH", "suffix": " analog is not affected. However, in clinical trials with bi"}, {"to": "1040", "prefix": "of patients who have been treated with bicalutamide and an ", "from": "1037", "name": "Gonadotropin-Releasing Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D007987", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "LHRH", "suffix": " agonist, and who discontinue bicalutamide therapy due to pr"}, {"to": "752", "prefix": " analog therapy, the suppression of serum ", "from": "741", "name": "Testosterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10379", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "testosterone", "suffix": " induced by the LHRH analog is not affected. However, in cli"}, {"to": "909", "prefix": "mide as a single agent for prostate cancer, rises in serum ", "from": "898", "name": "Testosterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10379", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "testosterone", "suffix": " and estradiol have been noted.\n                        In a"}, {"to": "923", "prefix": "agent for prostate cancer, rises in serum testosterone and ", "from": "915", "name": "Estradiol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004958", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "estradiol", "suffix": " have been noted.\n                        In a subset of pat"}, {"to": "264", "prefix": " Inducers: Avoid concomitant strong CYP3A4 inducers during ", "from": "259", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " treatment. If a strong CYP3A4 inducer must be co-administer"}, {"to": "347", "prefix": "trong CYP3A4 inducer must be co-administered, increase the ", "from": "342", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " dosing frequency. "}, {"to": "456", "prefix": "             CYP2D6 Substrates: Avoid co-administration of ", "from": "451", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " with CYP2D6 substrates that have a narrow therapeutic index"}, {"to": "958", "prefix": "          \n                        Based on in vitro data, ", "from": "953", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " is a substrate of CYP3A4.\n                        In a dedi"}, {"to": "1200", "prefix": "ne by 55%. Avoid concomitant strong CYP3A4 inducers during ", "from": "1195", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " treatment. If a strong CYP3A4 inducer must be co-administer"}, {"to": "1283", "prefix": "trong CYP3A4 inducer must be co-administered, increase the ", "from": "1278", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " dosing frequency [see Dosage and Administration "}, {"to": "1958", "prefix": "zing Enzymes\n                     \n                        ", "from": "1953", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " is an inhibitor of the hepatic drug-metabolizing enzymes CY"}, {"to": "2981", "prefix": "with a narrow therapeutic index if used concomitantly with ", "from": "2976", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " [see Clinical Pharmacology "}, {"to": "1077", "prefix": "n a dedicated drug interaction trial, co-administration of ", "from": "1070", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "rifampin", "suffix": ", a strong CYP3A4 inducer, decreased exposure of abiraterone"}, {"to": "1137", "prefix": "f rifampin, a strong CYP3A4 inducer, decreased exposure of ", "from": "1127", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " by 55%. Avoid concomitant strong CYP3A4 inducers during ZYT"}, {"to": "1634", "prefix": "no clinically meaningful effect on the pharmacokinetics of ", "from": "1624", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " [see Clinical Pharmacology "}, {"to": "1876", "prefix": "Effects of ", "from": "1866", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "Abiraterone", "suffix": " on Drug Metabolizing Enzymes\n                     \n        "}, {"to": "1528", "prefix": "n a dedicated drug interaction trial, co-administration of ", "from": "1517", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ketoconazole", "suffix": ", a strong inhibitor of CYP3A4, had no clinically meaningful"}, {"to": "2112", "prefix": " a CYP2D6 drug-drug interaction trial, the Cmax and AUC of ", "from": "2097", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "dextromethorphan", "suffix": " "}, {"to": "2201", "prefix": " were increased 2.8- and 2.9-fold, respectively, when ", "from": "2186", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "dextromethorphan", "suffix": " was given with abiraterone acetate 1,000 mg daily and predn"}, {"to": "2236", "prefix": "9-fold, respectively, when dextromethorphan was given with ", "from": "2218", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " 1,000 mg daily and prednisone 5 mg twice daily. Avoid co-ad"}, {"to": "2331", "prefix": "nd prednisone 5 mg twice daily. Avoid co-administration of ", "from": "2313", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " with substrates of CYP2D6 with a narrow therapeutic index "}, {"to": "2814", "prefix": "litazone was given together with a single dose of 1,000 mg ", "from": "2796", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": ". Therefore, patients should be monitored closely for signs "}, {"to": "2266", "prefix": "phan was given with abiraterone acetate 1,000 mg daily and ", "from": "2257", "name": "Prednisone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8640", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "prednisone", "suffix": " 5 mg twice daily. Avoid co-administration of abiraterone ac"}, {"to": "2409", "prefix": "e.g., ", "from": "2398", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "thioridazine", "suffix": ""}, {"to": "2686", "prefix": "rug-drug interaction trial in healthy subjects, the AUC of ", "from": "2675", "name": "pioglitazone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/33738", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "pioglitazone", "suffix": " "}, {"to": "2744", "prefix": " was increased by 46% when ", "from": "2733", "name": "pioglitazone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/33738", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "pioglitazone", "suffix": " was given together with a single dose of 1,000 mg abiratero"}, {"to": "279", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "Abiraterone acetate", "suffix": " "}, {"to": "2075", "prefix": "      \n                        Following administration of ", "from": "2057", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": ", the pharmacokinetics of abiraterone and abiraterone acetat"}, {"to": "2136", "prefix": "iraterone acetate, the pharmacokinetics of abiraterone and ", "from": "2118", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " have been studied in healthy subjects and in patients with "}, {"to": "2280", "prefix": ". In vivo, ", "from": "2262", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " is converted to abiraterone. In clinical studies, abiratero"}, {"to": "2350", "prefix": " acetate is converted to abiraterone. In clinical studies, ", "from": "2332", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " plasma concentrations were below detectable levels "}, {"to": "2811", "prefix": "                          Following oral administration of ", "from": "2793", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " to patients with metastatic CRPC, the median time to reach "}, {"to": "3085", "prefix": " compared to a single 1,000 mg dose of ", "from": "3067", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": ".\n                              At the dose of 1,000 mg dail"}, {"to": "3611", "prefix": "        Systemic exposure of abiraterone is increased when ", "from": "3593", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " is administered with food. In healthy subjects abiraterone "}, {"to": "3784", "prefix": " 7- and 5-fold higher, respectively, when a single dose of ", "from": "3766", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " was administered with a low-fat meal "}, {"to": "3943", "prefix": "7- and 10-fold higher, respectively, when a single dose of ", "from": "3925", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " was administered with a high-fat "}, {"to": "4156", "prefix": "ld or 1.6-fold higher, respectively, when a single dose of ", "from": "4138", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " was administered 2 hours after or 1 hour before a medium fa"}, {"to": "4420", "prefix": "in patients with metastatic CRPC, after repeated dosing of ", "from": "4402", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " were similar when abiraterone acetate was taken with low-fa"}, {"to": "4458", "prefix": "r repeated dosing of abiraterone acetate were similar when ", "from": "4440", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " was taken with low-fat meals for 7 days and increased appro"}, {"to": "5810", "prefix": "o studies show that at clinically relevant concentrations, ", "from": "5792", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " and abiraterone are not substrates of P-glycoprotein "}, {"to": "5899", "prefix": " and that ", "from": "5881", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " is an inhibitor of P-gp.\n                           \n      "}, {"to": "6351", "prefix": "                      Following oral administration of 14C-", "from": "6333", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " as capsules, abiraterone acetate is hydrolyzed to abiratero"}, {"to": "6384", "prefix": "ral administration of 14C-abiraterone acetate as capsules, ", "from": "6366", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " is hydrolyzed to abiraterone "}, {"to": "7447", "prefix": " 5 hours. Following oral administration of 14C-", "from": "7429", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": ", approximately 88% of the radioactive dose is recovered in "}, {"to": "7614", "prefix": " urine. The major compounds present in feces are unchanged ", "from": "7596", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " and abiraterone "}, {"to": "11467", "prefix": "d, respectively when dextromethorphan 30 mg was given with ", "from": "11449", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " 1,000 mg daily "}, {"to": "11748", "prefix": "           In a clinical study to determine the effects of ", "from": "11730", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " 1,000 mg daily "}, {"to": "12194", "prefix": " followed by a single dose of ", "from": "12176", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " 1,000 mg, the mean plasma AUC"}, {"to": "12795", "prefix": "litazone was given together with a single dose of 1,000 mg ", "from": "12777", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " [see Drug Interactions "}, {"to": "13818", "prefix": " due to ", "from": "13800", "name": "abiraterone acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100071", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone acetate", "suffix": " cannot be excluded due to study design limitations.\n       "}, {"to": "287", "prefix": "", "from": "282", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": ""}, {"to": "1408", "prefix": "n by the adrenals or in the tumor.\n                        ", "from": "1403", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " decreased serum testosterone and other androgens in patient"}, {"to": "1571", "prefix": "inical trial. It is not necessary to monitor the effect of ", "from": "1566", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " on serum testosterone levels.\n                        Chang"}, {"to": "4786", "prefix": " variation in the content and composition of meals, taking ", "from": "4781", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " with meals has the potential to result in increased and hig"}, {"to": "4956", "prefix": "ould be consumed for at least two hours before the dose of ", "from": "4951", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " is taken and for at least one hour after the dose of ZYTIGA"}, {"to": "5016", "prefix": "YTIGA is taken and for at least one hour after the dose of ", "from": "5011", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " is taken. The tablets should be swallowed whole with water "}, {"to": "10238", "prefix": ". In the ESRD cohort of the trial, a single 1,000 mg ", "from": "10233", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " dose was given under fasting conditions 1 hour after dialys"}, {"to": "13482", "prefix": "ingle-arm trial, 33 patients with metastatic CRPC received ", "from": "13477", "name": "Zytiga", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100076", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ZYTIGA", "suffix": " orally at a dose of 1,000 mg once daily at least 1 hour bef"}, {"to": "324", "prefix": " is converted in vivo to ", "from": "314", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": ", an androgen biosynthesis inhibitor, that inhibits 17 "}, {"to": "949", "prefix": "and are precursors of testosterone. Inhibition of CYP17 by ", "from": "939", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " can also result in increased mineralocorticoid production b"}, {"to": "2112", "prefix": "nistration of abiraterone acetate, the pharmacokinetics of ", "from": "2102", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " and abiraterone acetate have been studied in healthy subjec"}, {"to": "2308", "prefix": ". In vivo, abiraterone acetate is converted to ", "from": "2298", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": ". In clinical studies, abiraterone acetate plasma concentrat"}, {"to": "2897", "prefix": "h metastatic CRPC, the median time to reach maximum plasma ", "from": "2887", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " concentrations is 2 hours. Abiraterone accumulation is obse"}, {"to": "2936", "prefix": "each maximum plasma abiraterone concentrations is 2 hours. ", "from": "2926", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "Abiraterone", "suffix": " accumulation is observed at steady-state, with a 2-fold hig"}, {"to": "3573", "prefix": ".\n                              Systemic exposure of ", "from": "3563", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " is increased when abiraterone acetate is administered with "}, {"to": "3670", "prefix": "one acetate is administered with food. In healthy subjects ", "from": "3660", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " Cmax and AUC0"}, {"to": "4048", "prefix": " meal compared to overnight fasting. ", "from": "4038", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "Abiraterone", "suffix": " AUC0"}, {"to": "4341", "prefix": "sting.\n                              Systemic exposures of ", "from": "4331", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " in patients with metastatic CRPC, after repeated dosing of "}, {"to": "5549", "prefix": "                            \n                              ", "from": "5539", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "Abiraterone", "suffix": " is highly bound "}, {"to": "5826", "prefix": "linically relevant concentrations, abiraterone acetate and ", "from": "5816", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " are not substrates of P-glycoprotein "}, {"to": "6413", "prefix": " acetate as capsules, abiraterone acetate is hydrolyzed to ", "from": "6403", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " "}, {"to": "6603", "prefix": " not CYP mediated. The two main circulating metabolites of ", "from": "6593", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " in human plasma are abiraterone sulphate "}, {"to": "6635", "prefix": "circulating metabolites of abiraterone in human plasma are ", "from": "6625", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " sulphate "}, {"to": "6679", "prefix": " and N-oxide ", "from": "6669", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " sulphate "}, {"to": "6830", "prefix": "LT2A1 are the enzymes involved in the formation of N-oxide ", "from": "6820", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " sulphate and SULT2A1 is involved in the formation of abirat"}, {"to": "6895", "prefix": "erone sulphate and SULT2A1 is involved in the formation of ", "from": "6885", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " sulphate.\n                           \n                     "}, {"to": "7351", "prefix": "ients with metastatic CRPC, the mean terminal half-life of ", "from": "7341", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " in plasma "}, {"to": "7630", "prefix": "nds present in feces are unchanged abiraterone acetate and ", "from": "7620", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " "}, {"to": "8126", "prefix": "    \n                              The pharmacokinetics of ", "from": "8116", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " was examined in subjects with baseline mild "}, {"to": "8351", "prefix": "ubjects with normal hepatic function. Systemic exposure to ", "from": "8341", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " after a single oral 1,000 mg dose given under fasting condi"}, {"to": "8574", "prefix": "ne hepatic impairment, respectively. The mean half-life of ", "from": "8564", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " is prolonged to approximately 18 hours in subjects with mil"}, {"to": "8814", "prefix": "                 In another trial, the pharmacokinetics of ", "from": "8804", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " were examined in subjects with baseline severe "}, {"to": "9014", "prefix": " of ", "from": "9004", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " increased by approximately 7-fold in subjects with severe b"}, {"to": "10012", "prefix": "    \n                              The pharmacokinetics of ", "from": "10002", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " were examined in patients with end-stage renal disease "}, {"to": "10416", "prefix": "e collected up to 96 hours post dose. Systemic exposure to ", "from": "10406", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " after a single oral 1,000 mg dose did not increase in subje"}, {"to": "11123", "prefix": "In vitro studies with human hepatic microsomes showed that ", "from": "11113", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to "}, {"to": "11965", "prefix": "f theophylline was observed.\n                              ", "from": "11955", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "Abiraterone", "suffix": " is a substrate of CYP3A4, in vitro. In a clinical pharmacok"}, {"to": "12240", "prefix": " of ", "from": "12230", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " was decreased by 55% [see Drug Interactions "}, {"to": "12540", "prefix": "no clinically meaningful effect on the pharmacokinetics of ", "from": "12530", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " [see Drug Interactions "}, {"to": "12912", "prefix": "               \n                                 In vitro, ", "from": "12902", "name": "abiraterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1100072", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "abiraterone", "suffix": " and its major metabolites were shown to inhibit the hepatic"}, {"to": "634", "prefix": " the conversion of ", "from": "623", "name": "Pregnenolone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114052", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "pregnenolone", "suffix": " and progesterone to their 17"}, {"to": "651", "prefix": " the conversion of pregnenolone and ", "from": "640", "name": "Progesterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8727", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "progesterone", "suffix": " to their 17"}, {"to": "770", "prefix": " the subsequent formation of ", "from": "749", "name": "Dehydroepiandrosterone", "fullId": "http://purl.bioontology.org/ontology/MESH/D003687", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "dehydroepiandrosterone", "suffix": " "}, {"to": "776", "prefix": "", "from": "773", "name": "Dehydroepiandrosterone", "fullId": "http://purl.bioontology.org/ontology/MESH/D003687", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "DHEA", "suffix": ""}, {"to": "844", "prefix": " androstenedione, respectively, by C17, 20 lyase activity. ", "from": "841", "name": "Dehydroepiandrosterone", "fullId": "http://purl.bioontology.org/ontology/MESH/D003687", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "DHEA", "suffix": " and androstenedione are androgens and are precursors of tes"}, {"to": "797", "prefix": " and ", "from": "783", "name": "Androstenedione", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "androstenedione", "suffix": ", respectively, by C17, 20 lyase activity. DHEA and androste"}, {"to": "864", "prefix": "nedione, respectively, by C17, 20 lyase activity. DHEA and ", "from": "850", "name": "Androstenedione", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "androstenedione", "suffix": " are androgens and are precursors of testosterone. Inhibitio"}, {"to": "913", "prefix": "EA and androstenedione are androgens and are precursors of ", "from": "902", "name": "Testosterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10379", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "testosterone", "suffix": ". Inhibition of CYP17 by abiraterone can also result in incr"}, {"to": "1437", "prefix": " the tumor.\n                        ZYTIGA decreased serum ", "from": "1426", "name": "Testosterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10379", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "testosterone", "suffix": " and other androgens in patients in the placebo-controlled P"}, {"to": "1593", "prefix": " is not necessary to monitor the effect of ZYTIGA on serum ", "from": "1582", "name": "Testosterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10379", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "testosterone", "suffix": " levels.\n                        Changes in serum prostate s"}, {"to": "1238", "prefix": "ls. Androgen deprivation therapies, such as treatment with ", "from": "1235", "name": "Gonadotropin-Releasing Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D007987", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "GnRH", "suffix": " agonists or orchiectomy, decrease androgen production in th"}, {"to": "11338", "prefix": "n in vivo drug-drug interaction trial, the Cmax and AUC of ", "from": "11323", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "dextromethorphan", "suffix": " "}, {"to": "11426", "prefix": " were increased 2.8- and 2.9-fold, respectively when ", "from": "11411", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "dextromethorphan", "suffix": " 30 mg was given with abiraterone acetate 1,000 mg daily "}, {"to": "11585", "prefix": ". The AUC for dextrorphan, the active metabolite of ", "from": "11570", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "dextromethorphan", "suffix": ", increased approximately 1.3 fold [see Drug Interactions "}, {"to": "11499", "prefix": "plus ", "from": "11490", "name": "Prednisone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8640", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "prednisone", "suffix": " 5 mg twice daily"}, {"to": "11780", "prefix": "plus ", "from": "11771", "name": "Prednisone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8640", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "prednisone", "suffix": " 5 mg twice daily"}, {"to": "13600", "prefix": " 1 hour before or 2 hours after a meal in combination with ", "from": "13591", "name": "Prednisone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8640", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "prednisone", "suffix": " 5 mg orally twice daily. Assessments up to Cycle 2 Day 2 sh"}, {"to": "11542", "prefix": ". The AUC for ", "from": "11532", "name": "Dextrorphan", "fullId": "http://purl.bioontology.org/ontology/MESH/D003917", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "dextrorphan", "suffix": ", the active metabolite of dextromethorphan, increased appro"}, {"to": "11859", "prefix": " on a single 100 mg dose of the CYP1A2 substrate ", "from": "11848", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "theophylline", "suffix": ", no increase in systemic exposure of theophylline was obser"}, {"to": "11909", "prefix": "ubstrate theophylline, no increase in systemic exposure of ", "from": "11898", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "theophylline", "suffix": " was observed.\n                              Abiraterone is "}, {"to": "12119", "prefix": "", "from": "12112", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "rifampin", "suffix": ", 600 mg daily for 6 days"}, {"to": "12434", "prefix": "nteraction study of healthy subjects, co-administration of ", "from": "12423", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "ketoconazole", "suffix": ", a strong inhibitor of CYP3A4, had no clinically meaningful"}, {"to": "12686", "prefix": "rug-drug interaction trial in healthy subjects, the AUC of ", "from": "12675", "name": "pioglitazone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/33738", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "pioglitazone", "suffix": " was increased by 46% when pioglitazone was given together w"}, {"to": "12725", "prefix": "ubjects, the AUC of pioglitazone was increased by 46% when ", "from": "12714", "name": "pioglitazone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/33738", "setId": "4e338e89-3cf2-48eb-b6e2-a06c608c6513", "exact": "pioglitazone", "suffix": " was given together with a single dose of 1,000 mg abiratero"}, {"to": "177", "prefix": "nical studies have not shown any drug interactions between ", "from": "166", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " and LHRH analogs "}, {"to": "260", "prefix": ". There is no evidence that ", "from": "249", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " induces hepatic enzymes.\n                  \n               "}, {"to": "373", "prefix": "  \n                     In vitro studies have shown that R-", "from": "362", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " is an inhibitor of CYP 3A4 with lesser inhibitory effects o"}, {"to": "538", "prefix": "Clinical studies have shown that with co-administration of ", "from": "527", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": ", mean midazolam "}, {"to": "697", "prefix": ". Hence, caution should be exercised when ", "from": "686", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " is co-administered with CYP 3A4 substrates.\n               "}, {"to": "843", "prefix": "          In vitro protein-binding studies have shown that ", "from": "832", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " can displace coumarin anticoagulants from binding sites. Pr"}, {"to": "1032", "prefix": "ready receiving coumarin anticoagulants who are started on ", "from": "1021", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " and adjustment of the anticoagulant dose may be necessary.\n"}, {"to": "1247", "prefix": "    \n                        \n                           R-", "from": "1236", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " is an inhibitor of CYP 3A4; therefore, caution should be us"}, {"to": "1327", "prefix": "hibitor of CYP 3A4; therefore, caution should be used when ", "from": "1316", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": " is co-administered with CYP 3A4 substrates. "}, {"to": "1533", "prefix": "ready receiving coumarin anticoagulants who are started on ", "from": "1522", "name": "bicalutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83008", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "bicalutamide", "suffix": ". "}, {"to": "186", "prefix": "e not shown any drug interactions between bicalutamide and ", "from": "183", "name": "Gonadotropin-Releasing Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D007987", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "LHRH", "suffix": " analogs "}, {"to": "205", "prefix": "", "from": "197", "name": "Goserelin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017273", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "goserelin", "suffix": " or leuprolide"}, {"to": "219", "prefix": "goserelin or ", "from": "210", "name": "Leuprolide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42375", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "leuprolide", "suffix": ""}, {"to": "554", "prefix": "ve shown that with co-administration of bicalutamide, mean ", "from": "546", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D008874", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "midazolam", "suffix": " "}, {"to": "865", "prefix": "-binding studies have shown that bicalutamide can displace ", "from": "858", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2898", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "coumarin", "suffix": " anticoagulants from binding sites. Prothrombin times should"}, {"to": "985", "prefix": " should be closely monitored in patients already receiving ", "from": "978", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2898", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "coumarin", "suffix": " anticoagulants who are started on bicalutamide and adjustme"}, {"to": "1486", "prefix": "s should be closely monitored in patient already receiving ", "from": "1479", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2898", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "coumarin", "suffix": " anticoagulants who are started on bicalutamide. "}, {"to": "912", "prefix": "e can displace coumarin anticoagulants from binding sites. ", "from": "902", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "Prothrombin", "suffix": " times should be closely monitored in patients already recei"}, {"to": "1414", "prefix": "\n                           ", "from": "1404", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "7c295b64-ec39-42ec-9f02-da5b42e775e1", "exact": "Prothrombin", "suffix": " times should be closely monitored in patient already receiv"}]